In the current month, EIKN has received 4 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. EIKN average Analyst price target in the last month is 23.500.

2026-09

2026-08

2026-07

2026-06

2026-05

2026-04

2026-03

2026-02

Strong Buy

Buy

Hold

Strong Sell

Sell

Total

Financial Forecasting

Based on analysts' estimates, EIKN EPS is projected to reach -1.696 in FY2026Q3, following reported EPS of -1.633 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.

EPS

Revenue

Net Profit

EBIT

Forecast

Actual

FY2025Q4

FY2026Q1

FY2026Q2

FY2026Q3

FY2026Q4

Forecast

-1.74

-1.58

-1.70

-1.82

Actual

-1.48

-2.46

-1.63

Surprise

-41.15%

-3.02%

FAQs

How have Eikon Therapeutics Ord ShsEIKN's recent earnings per share performed?



The market expectation was USD -1.63, while Eikon Therapeutics Ord ShsEIKN's earnings per share (EPS) for the previous quarter was USD -2.46. EPS for the next quarter is expected at USD -1.82.

What is the analyst rating for Eikon Therapeutics Ord Shs?



Based on the ratings of Eikon Therapeutics Ord Shs's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.